
Improving Outcomes for Patients with Solid Tumors
OmniSeq INSIGHT® provides a comprehensive, easy-to-read report with clinical guidance for more precise, targeted therapies and trials for your patients.
INSIGHT'S Profiling Empowers
You to Make Better Decisions
From a single tumor biopsy, analyzed by advanced next generation sequencing (NGS) technology,
OmniSeq INSIGHT identifies treatment options in one comprehensive, easy-to-read report.

Genomic Profiling
- 523 Gene NGS Panel
- Microsatellite instability (MSI) and tumor mutational burden (TMB)
- DNA and RNA sequencing
- Single nucleotide variants (SNVs) – insertions/deletions (indels), copy number alterations (CNAs) and fusions
- Interrogation of full coding regions
- HLA genotyping
Immune Profiling
- PD-L1 by immunohistochemistry (IHC)
- 64 RNA expression/immune profiling genes by immune cycle step:
- T-cell priming/trafficking
- T-cell recognition
- T-cell infiltration
- Killing cancer cells
- Cancer testis antigens
Why Choose INSIGHT?
1
Single Tumor Biopsy
A single tissue sample provides complete insight into the tumor and its microenvironment.
2
Pan-Cancer Testing
The report provides comprehensive genomic and immune profiling for all solid tumors.
3
Treatment Options
A summary of FDA-approved therapies, immunotherapies and eligible clinical trials tailored to your patient’s solid tumor.
Identify Approved Drug Candidates
- Comprehensive Genomics
- Detects all four main classes of genomic alterations
- Fusions / splice variants using RNA-Seq hybrid capture
- Coverage of clinical practice guideline-recommended biomarkers across solid tumor types
Immunotherapy Eligibility
- Comprehensive Immune Profiling
- MSI & TMB profiling
- PD-L1 by IHC
- Immune biomarker drug targets
Eligible Clinical Trials
List of patient-eligible clinical trials within 200 miles of patient’s physical address1
- Testing for biomarkers with clinical trial associations
Precision Medicine Comparison —
Comprehensive Genomic and Immune Profiling
Result | Labcorp Oncology Omniseq INSIGHT | Foundation Medicine® FoundationOne®CDx | NeoGenomics® Neotype® Analysis Discovery Profile | Caris MI™ Profile Comprehensive Tumor Profiling | Tempus® XT V4 | |
---|---|---|---|---|---|---|
Genomic Profling | NGS for Targeted Therapy | 523 Genes | 324 Genes | 323 Genes | 700 at High Depth | 648 Genes |
RNA-Seq for Fusion Detection | Yes | No | Add on option | Whole Transcriptome | Whole Transcriptome | |
Tumor Signatures | Tumor Mutational Burden (TMB) | Yes | Yes | Yes | Yes | Yes |
Microsatellite Instability (MSI) | Yes | Yes | Yes | Yes | Yes | |
Tumor Micro-Environment | PD-L1 by IHC | Yes | Add on option | Yes | Yes | Add on option |
PD-L1/PD-L2 GEP* | Yes | No | No | No | No | |
CD3/CD8 GEP* | Yes | No | No | No | No | |
Immune Activation - Gene Expression by RNA-Seq | Yes | No | No | No | No | |
Tumor Infiltrating Lymphocytes (TILs) | Yes | No | No | No | No | |
Clinical Trials | Geocoded Clinical Trials for Targeted and Immunotherapy | Yes | Targeted Only Not Geocoded | Targeted Only Not Geocoded | Link to CT Connector (Chemo + Targeted Clinical Trials) | Targeted Only Geocoded But Not Tumor Specific |
- Genomic Profiling
Result: NGS for Targeted Therapy Labcorp Oncology Omniseq INSIGHT 523 Genes Foundation Medicine® FoundationOne®CDx 324 Genes NeoGenomics® Neotype® Analysis Discovery Profile 323 Genes Caris MI Profile™ Comprehensive Tumor Profiling 700 at High Depth Tempus® XT V4 648 Genes Result: RNA-Seq for Fusion Detection Labcorp Oncology Omniseq INSIGHT YesFoundation Medicine® FoundationOne®CDx NoNeoGenomics® Neotype® Analysis Discovery Profile Add on option Caris MI Profile™ Comprehensive Tumor Profiling Whole Transcriptome Tempus® XT V4 Whole Transcriptome - Tumor Signatures
Result: Tumor Mutational Burden (TMB) Labcorp Oncology Omniseq INSIGHT YesFoundation Medicine® FoundationOne®CDx YesNeoGenomics® Neotype® Analysis Discovery Profile YesCaris MI Profile™ Comprehensive Tumor Profiling YesTempus® XT V4 YesResult: Microsatellite Instability (MSI) Labcorp Oncology Omniseq INSIGHT YesFoundation Medicine® FoundationOne®CDx YesNeoGenomics® Neotype® Analysis Discovery Profile YesCaris MI Profile™ Comprehensive Tumor Profiling YesTempus® XT V4 Yes - Tumor Micro-Environment
Result: PD-L1 by IHC Labcorp Oncology Omniseq INSIGHT YesFoundation Medicine® FoundationOne®CDx Add on option NeoGenomics® Neotype® Analysis Discovery Profile YesCaris MI Profile™ Comprehensive Tumor Profiling YesTempus® XT V4 Add on option Result: PD-L1/PD-L2 GEP* Labcorp Oncology Omniseq INSIGHT YesFoundation Medicine® FoundationOne®CDx NoNeoGenomics® Neotype® Analysis Discovery Profile NoCaris MI Profile™ Comprehensive Tumor Profiling NoTempus® XT V4 NoResult: CD3/CD8 GEP* Labcorp Oncology Omniseq INSIGHT YesFoundation Medicine® FoundationOne®CDx NoNeoGenomics® Neotype® Analysis Discovery Profile NoCaris MI Profile™ Comprehensive Tumor Profiling NoTempus® XT V4 NoResult: Immune Activation - Gene Expression by RNA-Seq Labcorp Oncology Omniseq INSIGHT YesFoundation Medicine® FoundationOne®CDx NoNeoGenomics® Neotype® Analysis Discovery Profile NoCaris MI Profile™ Comprehensive Tumor Profiling NoTempus® XT V4 NoResult: Tumor Infiltrating Lymphocytes (TILs) Labcorp Oncology Omniseq INSIGHT YesFoundation Medicine® FoundationOne®CDx NoNeoGenomics® Neotype® Analysis Discovery Profile NoCaris MI Profile™ Comprehensive Tumor Profiling NoTempus® XT V4 No - Clinical Trials
Result: Geocoded Clinical Trials for Targeted and Immunotherapy Labcorp Oncology Omniseq INSIGHT YesFoundation Medicine® FoundationOne®CDx Targeted Only
Not GeocodedNeoGenomics® Neotype® Analysis Discovery Profile Targeted Only
Not GeocodedCaris MI Profile™ Comprehensive Tumor Profiling Link to CT Connector
(Chemo + Targeted Clinical Trials)Tempus® XT V4 Targeted Only
Geocoded But Not Tumor Specific
*GEP - genomic expression profiling
Data as of June 16, 2021
Patient Reports: Concise, Comprehensive & Actionable
Comprehensive Quick-Read Results
Gain actionable insights at a glance with:
- Clinically significant results
- Pertinent negative genomic variants
- A therapy considerations summary
- Flagged potential cancer-associated hereditary variants
THERAPY CONSIDERATIONS
Start to formulate a plan with:
- Full-label indications
- Treatment setting and approval status
- Guideline evidence
- Emerging clinical benefits
MARKER DETAILS
See the bigger picture with:
- Full biomarker details
- Gene, variant and prevalence information
Clinical Trial Options
Expand your patient’s options with:
- Number of trial matches per marker
- Clinical significance for matched trials
- Highly-expressed/positive immune genes with trials
Sample requirements (include pathology report) |
---|
Formalin fixed paraffin embedded (FFPE) tissue
**Do not submit decalcified specimens, cytology smears or samples from hematologic malignancies** |
FFPE block (preferred) or 20 unbaked, positively charged, unstained slides cut a 5 µm plus one H&E |
Turnaround time: 12-14 Days |
See test menu for additional information
OmniSeq High Laboratory Quality Standards
- NYS CLEP approved
- ISO 13485 (2016) certified
- CLIA and CAP accredited
Labcorp Broad National Coverage
- In-network with most major health plans
- 1,600 contractual relationships with plans, payers and other healthcare organizations
References
1. OmniSeq Bioinformatics Knowledgebase - data curation January 2021.